Join Us

December 2010 Research News

Save as Favorite
Sign in to receive recommendations (Learn more)

Experts Offer Opinions on Mammography Recommendations
December 23, 2010
Experts offer opinions on the U.S. Preventive Services Task Force's controversial recommendations to breast cancer screening guidelines that were issued in November 2009. Read more...

Abdominal Fat May Increase Risk of Hormone-Receptor-Negative Disease
December 16, 2010
New research suggests that premenopausal women with a large amount of abdominal fat have a higher risk of hormone-receptor-negative breast cancer than women with less abdominal fat. Read more...

FDA Recommends Removing Avastin’s Breast Cancer Indication
December 16, 2010
The FDA has recommended removing the breast cancer indication from Avastin because the medicine has not been shown to be safe and effective for that use. Read more...

Xeloda Doesn’t Seem to Reduce Recurrence Risk
December 15, 2010
A new study shows that the risk of recurrence is the same whether or not Xeloda was added to a standard adjuvant chemotherapy regimen for early-stage breast cancer with a high risk of recurrence. Read more...

Circulating Tumor Cells Linked to Worse Prognosis
December 15, 2010
New studies suggest that even one circulating tumor cell in a blood sample from a woman diagnosed with breast cancer is linked to a worse prognosis. Read more...

Giving Chemo and Radiation Therapy at Same Time Offers Same Benefits as Sequential Timing
December 14, 2010
Research suggests that giving radiation therapy at the same time as chemotherapy -- in between cycles or even during cycles -- offers the same benefits as the traditional approach (chemotherapy followed by radiation) in less time. Read more...

Experimental Combo of Herceptin and Omnitarg Helps Treat Advanced-Stage HER2-Postitive Disease
December 14, 2010
Treatment before surgery with Herceptin and Omnitarg alone or with Taxotere benefited women diagnosed with locally-advanced or inflammatory HER2-positive breast cancer. Read more...

Chemo During Pregnancy Doesn’t Harm Baby
December 14, 2010
New research supports other studies that suggest that chemotherapy during pregnancy doesn't have harmful effects on the baby. Read more...

Link Between Obesity and Worse Prognosis Isn’t Consistent
December 14, 2010
The analysis of several studies show the link between obesity and worse prognosis in women diagnosed with early-stage breast cancer isn't consistent. Read more...

Consider Second Opinion if HER2 Test is Negative
December 14, 2010
Research suggests that HER2 test results may not be interpreted correctly, even at expert labs. Read more...

Real World Survival Stats for Avastin Mirror Clinical Results
December 13, 2010
Analysis shows that the real world survival statistics of women diagnosed with metastatic breast cancer and treated with chemotherapy and Avastin were similar to survival statistics of women in clinical trials looking at the same combination. Read more...

Experimental Iniparib Shows Promise in Treating Advanced-Stage Disease
December 13, 2010
A small, early study suggests that some advanced-stage cancers may respond to an experimental combination of iniparib and Camptosar. Read more...

Researchers Recommend Having Port in Place for Week Before Starting Avastin
December 13, 2010
Research shows that doctors should wait at least 1 week after a venous access line is put in before giving Avastin. Read more...

Pathologic Complete Response to Treatment Before Surgery Linked to Better Prognosis
December 12, 2010
Research found that women who got neoadjuvant treatment and had a complete pathologic response were less likely to have the cancer come back compared to women who didn't have a complete pathologic response. Read more...

Prophylactic Brain Radiation Therapy Doesn’t Seem to Cause Cognitive Problems
December 12, 2010
A small, early study found that preventive cranial radiation in addition to Herceptin and chemotherapy didn't cause more or different cognitive problems than Herceptin and chemotherapy alone in women diagnosed with HER2-positive metastatic breast cancer. Read more...

Xgeva Better Than Zometa at Reducing Risk of Breast Cancer Bone Problems
December 12, 2010
Research has found that Xgeva (chemical name: denosumab), a new targeted therapy medicine, is better than Zometa at lengthening the time before bone complications develop in women diagnosed with breast cancer that has spread to the bones. Read more... 

Herceptin More Effective Than Tykerb When Given Before Surgery
December 11, 2010
Research suggests that Herceptin is more effective than Tykerb in a neoadjuvant regimen for early-stage or locally-advanced HER2-positive breast cancer. Read more...

Herceptin and Tykerb Added to Chemo Before Surgery More Effective Than Adding Only One to Treat Early-Stage, HER2-Positive Disease
December 11, 2010
Giving both Herceptin and Tykerb with paclitaxel before surgery for HER2-positive breast cancer offered more benefits than Herceptin or Tykerb alone with paclitaxel new research shows. Read more...

Arimidex and Aromasin Equally Good at Reducing Recurrence Risk
December 11, 2010
A new study shows that Arimidex and Aromasin are equally good at reducing the risk of recurrence in postmenopausal women diagnosed with early-stage, hormone-receptor-positive breast cancer. Read more...

Avastin Added to Chemo Before Surgery Offers No Benefit
December 11, 2010
Research shows that adding Avastin to neoadjuvant chemotherapy doesn't seem to benefit women diagnosed with early-stage or locally-advanced breast cancer. Read more...

Herceptin-Tykerb-Chemo Combo Before Surgery May Help Treat Early-Stage HER2-Positive Disease
December 11, 2010

Early results suggest that a combination of four medicines given BEFORE surgery to treat HER2-positive, early-stage breast cancer may be a good way to weaken and destroy breast cancer cells. Read more...

Aromatase Inhibitors Increase Risk of Heart Problems
December 10, 2010
Women diagnosed with early-stage, hormone-receptor-positive breast cancer who got 5 years of an aromatase inhibitor seem to be more likely to have heart problems compared to women who got 5 years of tamoxifen. Read more...

Only About 50% of Women 40 and Older Getting Screening Mammograms
December 10, 2010
Even before the public outcry about the proposed changes to mammogram guidelines, only about half of women age 40 and older were getting screened as recommended. Read more...

Results Not Clear on Whether Zometa Reduces Recurrence Risk
December 9, 2010

Two studies looking at whether Zometa could reduce the risk of early-stage breast cancer coming back (recurrence) offered conflicting results. Read more...

Careful Weight Lifting Doesn’t Increase Lymphedema Risk
December 8, 2010
Research suggests that a careful weight lifting program that starts with light weights and gradually increases after breast cancer surgery doesn't increase lymphedema risk and could possibly lower the risk of developing lymphedema. Read more...

Radiation, Tamoxifen After DCIS Surgery Reduces Recurrence Risk
December 7, 2010
Research shows that radiation therapy and hormonal therapy after surgery for DCIS reduces the risk of being diagnosed with either another DCIS or invasive breast cancer in the future. Read more...

Doctors Continue to Prescribe Standard-Dose Hormone Replacement Therapy
December 3, 2010
Despite a clear link between standard-dose HRT and breast cancer, many doctors continue to regularly prescribe standard-dose HRT instead of low-dose HRT. Read more...

Taxotere Better Than Fluorouracil in Chemo Regimen After Surgery for Early-Stage Disease
December 1, 2010

Chemotherapy that included Taxotere offered slightly better results than a regimen that included 5-FU for women diagnosed with early-stage breast cancer that hadn't spread to the lymph nodes, but Taxotere was more likely to cause serious side effects. Read more...

Was this article helpful? Yes / No
Rn icon

Can we help guide you?

Create a profile for better recommendations

How does this work? Learn more
Are these recommendations helpful? Take a quick survey

Fy22oct sidebarad v02
Back to Top